https://www.selleckchem.com/pr....oducts/Rapamycin.htm
Sunitinib is listed as first-line therapy for non clear-cell renal cell carcinoma (RCC) in several guidelines. However, in the era of immunotherapy, there is an urgent need for updated evidence for the treatment of metastatic non clear-cell RCC. Herein, we present three cases of patients with type 2 papillary RCC who were effectively treated with cabozantinib. The first case was a 48-year-old woman who underwent radical nephrectomy (pT3aN0M. The tumor relapsed in the retroperitoneum 3 months postoperatively and was unresponsive to f
Like
Comment
Share
